Drugs of Abuse (DOA) Testing Market Report 2026

The drugs of abuse (doa) testing market size has grown strongly in recent years. It will grow from $7.97 billion in 2025 to $8.68 billion in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to workplace safety regulations, substance abuse prevalence, criminal justice screening needs, immunoassay testing adoption, laboratory infrastructure expansion.

The drugs of abuse (doa) testing market size is expected to see strong growth in the next few years. It will grow to $12.17 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to remote workplace testing demand, oral fluid testing growth, real-time data integration, regulatory enforcement expansion, public health monitoring programs. Major trends in the forecast period include rising adoption of workplace drug screening programs, growing demand for rapid point-of-care testing, expansion of multi-panel drug testing kits, increased use of laboratory confirmation testing, integration of digital reporting and data management.

The rising demand for drug abuse treatment is expected to drive the growth of the drugs of abuse (DOA) testing market in the coming years. Drug abuse, or substance abuse, refers to the consumption of substances in quantities that are harmful to the user or others. Drug testing helps identify compounds not normally present in the body. The process typically begins with a screening test, followed by a confirmatory test to detect or verify the presence of one or more substances, meaning that growing demand for drug abuse treatment will boost market growth. For instance, in December 2023, the Government of the United Kingdom (GOV.UK) reported that between April 2022 and March 2023, 290,635 adults accessed drug and alcohol services, a slight increase from 289,215 in the previous year. Treatment admissions also rose to 137,749, compared to 130,490 and 133,704 in the prior two years. Therefore, increasing demand for drug abuse treatment is supporting the growth of the DOA testing market.

Major companies in the drugs of abuse (DOA) testing market are focusing on developing innovative solutions such as software-as-a-service (SaaS) platforms to improve testing efficiency, optimize data management, and strengthen competitive positioning. A SaaS platform is a cloud-based application hosted by a third-party provider and accessed via the internet, allowing users to streamline workflows, analyze complex datasets, and gain actionable insights without installing software locally. For example, in December 2023, Merck KGaA, a US-based science and technology company, launched Addison, an advanced drug discovery software platform that integrates computer-aided drug design, machine learning, and generative AI to accelerate drug development. The platform provides synthesis recommendations for virtual molecules, links digital drug design with practical manufacturability, and uncovers insights from large datasets, ultimately increasing the likelihood of delivering effective new therapies to patients.

In June 2024, Premier Biotech Inc., a US-based biotechnology company, acquired Desert Tox LLC for an undisclosed amount. Through this acquisition, Premier Biotech aims to expand its portfolio of affordable drug misuse screening solutions and enhance the accessibility and effectiveness of drug testing services. Desert Tox LLC is a US-based company specializing in toxicology and drug testing solutions.

Major companies operating in the drugs of abuse (doa) testing market are Siemens AG, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Laboratory Corporation of America Holdings, Quest Diagnostics Inc., bioMérieux Inc., Dragerwerk AG & Co. KGaA, Aegis Sciences Corporation, NMS Labs, Clinical Reference Laboratory Inc., Cordant Health Solutions, Millennium Health, ACM Global Laboratories, Psychemedics Corporation, Alfa Scientific Designs Inc., Alere Toxicology Services, Omega Laboratories Inc., BioTek Laboratories, Premier Biotech Inc., Dominion Diagnostics LLC, Randox Toxicology Ltd., Cansford Laboratories Ltd., United States Drug Testing Laboratories Inc., American Bio Medica Corporation, Confirm BioSciences, Immunalysis Corporation, Medtox Diagnostics Inc., Forensic Fluids Laboratories.

North America was the largest region in the drugs of abuse (DOA) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global drugs of abuse (DOA) testing market report during the forecast period. The regions covered in the drugs of abuse (doa) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drugs of abuse (doa) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the drugs of abuse testing market by increasing costs of imported analyzers, rapid testing devices, reagents, and consumables. Diagnostic laboratories and forensic facilities in North America and Europe are most affected due to reliance on imported testing equipment. These tariffs raise testing costs but encourage domestic production of test kits and regional manufacturing of diagnostic consumables.

The drugs of abuse (doa) testing market research report is one of a series of new reports that provides drugs of abuse (doa) testing market statistics, including drugs of abuse (doa) testing industry global market size, regional shares, competitors with a drugs of abuse (doa) testing market share, detailed drugs of abuse (doa) testing market segments, market trends and opportunities, and any further data you may need to thrive in the drugs of abuse (doa) testing industry. This drugs of abuse (doa) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Drug of abuse (DOA) testing refers to the analysis of substances, such as drugs, chemicals, or plant products, that are commonly used recreationally. This includes marijuana, cocaine, opioids, amphetamines, alcohol, and PCP, which are typically tested as part of a drug panel. Samples for this clinical screening procedure may include urine, saliva, blood, hair, or sweat.

The main products and services for drug of abuse (DOA) testing include analyzers, rapid testing devices, consumables, and laboratory services. An analyzer is a device that automatically measures the chemical concentration of one or more components or other related physical quantities, either continuously or intermittently. Sample types include urine, hair, oral fluid, and breath, and these tests are used in applications such as pain management, criminal justice, and workplace screening. End users include hospitals, diagnostic laboratories, forensic laboratories, and others.

The drugs of abuse (DOA) testing market includes revenues earned by entities by providing services such as analyzers, rapid testing devices, consumables, and laboratory services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.